Silexion Therapeutics to be Acquired by 03 Life Sciences
Ticker: SLXNW · Form: 8-K · Filed: Jul 29, 2025 · CIK: 2022416
Sentiment: neutral
Topics: acquisition, merger, biotech
Related Tickers: SLXN
TL;DR
Silexion Therapeutics is being bought by 03 Life Sciences, deal expected to close Q4 2025.
AI Summary
Silexion Therapeutics Corp. announced on July 29, 2025, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is expected to close in the fourth quarter of 2025. This acquisition follows Silexion's name change from Biomotion Sciences on May 6, 2024.
Why It Matters
This acquisition signifies a consolidation within the biotechnology sector, potentially impacting Silexion's ongoing research and development pipeline and its shareholders.
Risk Assessment
Risk Level: medium — Acquisition news can introduce volatility as the market assesses the deal terms and future integration.
Key Players & Entities
- Silexion Therapeutics Corp (company) — Registrant
- 03 Life Sciences (company) — Acquiring entity
- Biomotion Sciences (company) — Former company name
- May 6, 2024 (date) — Date of name change
- July 29, 2025 (date) — Report date
- July 28, 2025 (date) — Earliest event reported date
- Fourth quarter of 2025 (date) — Expected closing date of acquisition
FAQ
What is the primary reason for the acquisition of Silexion Therapeutics by 03 Life Sciences?
The filing does not explicitly state the primary reason for the acquisition, but it announces the definitive agreement for 03 Life Sciences to acquire Silexion Therapeutics.
When is the acquisition of Silexion Therapeutics expected to be completed?
The acquisition is expected to close in the fourth quarter of 2025.
What was Silexion Therapeutics Corp. previously known as?
Silexion Therapeutics Corp. was formerly known as Biomotion Sciences, with a name change occurring on May 6, 2024.
What is the reporting date for this 8-K filing?
The report date is July 29, 2025, with the earliest event reported being July 28, 2025.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 29, 2025 regarding Silexion Therapeutics Corp (SLXNW).